SEC Comment Letter for Scopus BioPharma Inc. (SCPS) (CIK 0001772028) — Jan 10, 2022
Scopus BioPharma Inc. (SCPS) (CIK 0001772028)
Date: Jan. 10, 2022 · CIK: 0001772028 · Accession: 0000000000-22-000261
AI Filing Summary & Sentiment
File numbers found in text: 333-261991
Letter
United States securities and exchange commission logo January 10, 2022 Joshua Lamstein Chairman Scopus BioPharma Inc. 420 Lexington Avenue, Suite 300 New York, New York 10170 Re:Scopus BioPharma Inc. Registration Statement on Form S-3 Filed January 4, 2022 File No. 333-261991 Dear Mr. Lamstein: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Anna Tomczyk
Show Raw Text
United States securities and exchange commission logo
January 10, 2022
Joshua Lamstein
Chairman
Scopus BioPharma Inc.
420 Lexington Avenue, Suite 300
New York, New York 10170
Re:Scopus BioPharma Inc.
Registration Statement on Form S-3
Filed January 4, 2022
File No. 333-261991
Dear Mr. Lamstein:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Anna Tomczyk